Mechanisms of resistance to cisplatin

Kartalou, Maria; Essigmann, John M.

doi:10.1016/s0027-5107(01)00141-5

Cited by 821 publications

(725 citation statements)

References 155 publications

Supporting

Mentioning

700

Contrasting

Unclassified

Order By: Relevance

“…It is a platinum-based compound that forms intra-and inter-strand adducts with DNA, thus it is a potent inducer of cell cycle arrest, and apoptosis in most cancer cell types (Schloffer et al, 2003). However, a major limitation of chemotherapy is that many tumors either are inherently resistant or acquire resistance to the drug after an initial response (Kartalou et al, 2001). Tremendous efforts are being made to improve the anticancer effect of Cisplatin.…”

Section: Discussionmentioning

confidence: 99%

“…However, the administration of Cisplatin is associated with serious side effects, including nephrotoxicity, hepatotoxicity, and neurotoxicity. Furthermore, in advanced stages of cervical cancer, intrinsic resistance to Cisplatin is developed due to several factors (Kartalou et al, 2001). Therefore, new agents or new regimens in combination with Cisplatin are being sought in order to increase anticancer activity and decrease adverse effects (Jurado et al, 2009).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Induction of Mitochondrial-Mediated Apoptosis by Morinda Citrifolia (Noni) in Human Cervical Cancer Cells

Gupta¹,

Banerjee²,

Pathak³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Induction of Mitochondrial-Mediated Apoptosis by Morinda Citrifolia (Noni) in Human Cervical Cancer Cells

Gupta¹,

Banerjee²,

Pathak³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Cisplatin's structure has a square planar geometry with a platinum molecule in the middle and two reactive chloride ions and two amide groups extending from it [35]. The active form of cisplatin can interact with nucleophilic sites on DNA and form DNA-platinum adducts [36].…”

Section: Dna Repair Proteinmentioning

confidence: 99%

Searching for potential biomarkers of cisplatin resistance in human ovarian cancer using a label‐free LC/MS‐based protein quantification method

Fitzpatrick

You²,

Bemis³

et al. 2007

Proteomics Clinical Apps

View full text Add to dashboard Cite

Platinum-based chemotherapy, such as cisplatin, is the primary treatment for ovarian cancer. However, drug resistance has become a major impediment to the successful treatment of ovarian cancer. To date, the molecular mechanisms of resistance to platinum-based chemotherapy remain unclear. In this study, we applied an LC/MS-based protein quantification method to examine the global protein expression of two pairs of ovarian cancer cell lines, A2780/A2780-CP (cisplatin-sensitive/cisplatin-resistant) and 2008/2008-C13*5.25 (cisplatin-sensitive/cisplatinresistant). We identified and quantified over 2000 proteins from these cell lines and 760 proteins showed significant expression changes with a false discovery rate of less than 5% between paired groups. Based on the results we obtained, we suggest several potential pathways that may be involved in cisplatin resistance in human ovarian cancer. This study provides not only a new proteomic platform for large-scale quantitative protein analysis, but also important information for discovery of potential biomarkers of cisplatin resistance in ovarian cancer. Furthermore, these results may be clinically relevant for diagnostics, prognostics, and therapeutic improvement for ovarian cancer treatment.

show abstract

“…Intrinsic and/or acquired resistance as well as toxicities associated with cisplatin are major limitations of this drug [1,4,6,10,11]. For example, about 85% of ovarian cancer patients relapse following initial response [1].…”

Section: Introductionmentioning

confidence: 99%

Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis

Shukla

Duan²,

Badner³

et al. 2008

Pharmacogenetics and Genomics

View full text Add to dashboard Cite

Objectives-Cisplatin is a widely used chemotherapeutic agent; however, nephrotoxicity and neuropathy are obstacles for drug efficacy. Little is known about the genes or genetic variants contributing to the risk of developing these toxicities or chemotherapeutic response. Thus, we have applied a cell-based model to identify and characterize previously unknown genes that may be involved in cellular susceptibility to cisplatin.Methods-Lymphoblastoid cell lines from 27 large Centre d'Etude du Polymorphisme Humain pedigrees were used to elucidate the genetic contribution to cisplatin-induced cytotoxicity. Phenotype was defined as cell growth inhibition following exposure of cell lines to increasing concentrations of cisplatin for 48 h.Results-Significant heritability, ranging from 0.32 to 0.43 (P < 10 −7 ), was found for the cytotoxic effects of each concentration (1, 2.5, 5, 10, and 20 μmol/l) and IC50, the concentration required for 50% cell growth inhibition. Linkage analysis revealed 11 genomic regions on six chromosomes with logarithm of odds (LOD) scores above 1.5 for cytotoxic phenotypes. The highest LOD score was found on chromosome 4q21.3−q35.2 (LOD = 2.65, P = 2.4 × 10 −4 ) for 5 μmol/l cisplatin. Quantitative transmission disequilibrium tests were performed using 191 973 nonredundant single nucleotide polymorphisms (SNPs) located in the 1 LOD confidence interval of these 11 regions. Twenty SNPs, with 10 SNPs located in five genes, were significantly associated with cisplatin-induced cytotoxicity (P ≤ 1 × 10 −4 ). Four of these 20 SNPs were found to explain over 10% of the variation in cisplatininduced apoptosis.Conclusions-Our results suggest that genetic factors involved in cytotoxicity also contribute to cisplatin-induced apoptosis. These cell lines provide a paradigm to identify previously unknown pharmacogenetic variants associated with drug cytotoxicity.

show abstract

Mechanisms of resistance to cisplatin

Cited by 821 publications

References 155 publications

Induction of Mitochondrial-Mediated Apoptosis by Morinda Citrifolia (Noni) in Human Cervical Cancer Cells

Induction of Mitochondrial-Mediated Apoptosis by Morinda Citrifolia (Noni) in Human Cervical Cancer Cells

Searching for potential biomarkers of cisplatin resistance in human ovarian cancer using a label‐free LC/MS‐based protein quantification method

Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis

Contact Info

Product

Resources

About